Integrative Proteogenomics and Single-Cell Transcriptomics Prioritize Candidate Causal Proteins and Therapeutic Targets in Age-Related Macular Degeneration
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188103 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Lei Wen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China. Hauptthemen laut MEDLINE: Macular Degeneration, Proteogenomics, Transcriptome. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Basic Research Program of Jiangsu.
Abstract (Originalsprache)
Age-related macular degeneration (AMD) is a major cause of irreversible visual impairment, yet identifying effector proteins and tissue-specific mechanisms underlying genome-wide association study (GWAS) loci remains challenging. This study aimed to systematically prioritize candidate causal circulating proteins and delineate their cellular and transcriptional dynamics in AMD. We integrated plasma protein quantitative trait loci (pQTL) summary statistics from the UK Biobank Pharma Proteomics Project (UKB-PPP; N=53,022) with FinnGen AMD GWAS data using proteome-wide association studies (PWAS), summary-data-based Mendelian randomization (SMR) with the HEIDI test, and Bayesian colocalization analysis. Prioritized candidates were mapped across human and murine retinal single-cell/single-nucleus RNA sequencing atlases. Transcriptional responsiveness was validated in an independent clinical microarray dataset (GSE103060) and in human retinal pigment epithelial cells (ARPE-19) via in vitro inflammatory stimulation and RT-qPCR. Target tractability was assessed using pharmacological databases. Multi-stage genetic screening prioritized five candidate proteins stratified into two confidence tiers: three Tier 1 causal drivers supported by colocalization (PP4 > 0.80)—including risk factors CSF2, IL20RB, and WARS1 (also known as WARS)—alongside two Tier 2 candidates supported by SMR and HEIDI, comprising risk factor PILRA and inversely associated metabolic factor ACADSB. Retinal transcriptomic mapping localized PILRA specifically to microglia, ACADSB to inner retinal neurons, and WARS1 to photoreceptors, RPE, and vascular compartments, while IL20RB and CSF2 exhibited low baseline expression. In independent validation cohorts, IL20RB and WARS1 were significantly up-regulated in choroidal neovascularization (CNV) membrane-derived RPE from patients with AMD (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
- School of Food Science and Technology, Jiangnan University, Wuxi 214122, China.
Förderung
- National Natural Science Foundation of China
- Basic Research Program of Jiangsu
Zitieren
APA
Wen, L., Li, F., Liu, Y., Zhang, K., Mao, A., Liu, L., Lv, X., Geng, L., Yu, F., Feng, L., & Kan, H. (2026). Integrative Proteogenomics and Single-Cell Transcriptomics Prioritize Candidate Causal Proteins and Therapeutic Targets in Age-Related Macular Degeneration. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188103
Vancouver
Wen L, Li F, Liu Y, Zhang K, Mao A, Liu L, et al. Integrative Proteogenomics and Single-Cell Transcriptomics Prioritize Candidate Causal Proteins and Therapeutic Targets in Age-Related Macular Degeneration. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188103
BibTeX
@article{Wen2026,
author = {Wen, Lei and Li, Fangran and Liu, Yuan and Zhang, Ka and Mao, Aiqin and Liu, Liangju and Lv, Xiaowang and Geng, Li and Yu, Fan and Feng, Lei and Kan, Hao},
title = {Integrative Proteogenomics and Single-Cell Transcriptomics Prioritize Candidate Causal Proteins and Therapeutic Targets in Age-Related Macular Degeneration},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188103}
}
EUVIMED